OBI Pharma confirms FDA’s clearance of IND for Phase 1 Study of Monoclonal Antibody Cancer…
U.S FDA clears OBI Pharma's investigational new drug (IND) application for a Phase 1 study of a monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen…
Read More...
Read More...
